equivocal. Given their unique capacity to present antigens to naive T cells, it was postulated that perhaps cells of dendritic leukocyte lineage may playa vital role in allosensitization 8 • Supporting evidence for the latter argument came from the initial studies by Lechler and Batchelor, who demonstrated that allogeneic kidneys were indefinitely accepted in rodents if they were initially "parked" in an immunosuppressed recipient prior to retransplantation into a secondary naive syngeneic animal 9 • More importantly, the allografts were acutely rejected if DC obtained from donor-strain animals were infused into the secondary recipients indicating that the latter manipulation perhaps, led to the restoration of immunogenicity of the leukocyte-depleted allograft resulting in its prompt rejection. This and numerous subsequent studies l ()"12 have unambiguously established the identity of donor DC as the critical passenger leukocytes primarily responsible for allograft rejection, supporting the concept that their elimination prior to Tx may possibly culminate in prolonged graft survival.
DC in Transplantation Tolerance
A diametrical yet entirely compatible role for DC has been proposed by recent studies in rodents '3 • 14 and sub-human primates 's . Our laboratory has shown previously that livers transplanted orthotopically across most mouse strain combinations are spontaneously accepted '6 . Interestingly, DC isolated from murine livers exhibit phenotype and function distinctive of that of immature cells, suggesting perhaps that upon migration from the graft into the host, these cells may provide "deviant" signals resulting in induction of donor-specific hyporeactivity rather than allosensitization 13. It is interesting to note that organs other than livers which are promptly rejected following Tx also contain, albeit few, resident immature DC". It is therefore entirely conceivable that the inherent tolerogenicity uniquely ascribed to murine livers may be contingent on the presence within it an apropos quality and quantity of resident leukocytes bearing an immature phenotype.
Chimerism and Its Role in Organ Allograft Acceptance
The ubiquitous detection of the presence of donor cell chimerism in the tissues of successful long-term human kidney and liver recipients provided irrevocable evidence for the role of microchimerism in Tx tolerance I8 . 19 • These observations were supported by contemporaneous studies in rodents prompting evolvement of a hypothesis that the establishment of microchimerism by migratory resident leukocytes may playa seminal role in the induction of donor-specific tolerance 13 . IS. 20.21 . Whilst the role of migratory donor cells in the induction of donor-specific hyporeactivity was undeniable, the mechanism responsible for the perpetuation of chimerism and therefore of tolerance, years after organ Tx was nevertheless unclear. However, recent studies in rodents 22 • 23 and humans 24 , have confirmed the presence of pluripotent stem cells in the interstitium of the grafted organ providing explication for the long-term persistence of donor cell chimerism.
AUGMENTATION OF CHIMERISM IN HUMAN ALLOGRAFT RECIPIENTS
Recognizing the seminal role played by migratory donor leukocytes in allograft acceptance and the induction of donor-specific tolerance almost four years ago, we embarked on a prospective clinical trial to augment the phenomenon in organ recipients by peri operative donor bone marrow (BM) infusion. In addition to verifying the safety of this procedure, three long-term goals of this study were to: (i) prevent delayed graft rejection, (ii) abrogate or mitigate chronic rejection and (iii) to decrease drug-dependence. Since June 1992, lS9 recipients of liver (n=55), kidney (n=36), kidney + pancreas (n=33), kidney + islets (n=7), heart (n=24), lungs (n=IS), small bowel (n=!3) and multi-organ (n=3) have received a single peri-operative infusion of 3-{)x 10 8 BM cells/kg body weight. Additionally, subsequent to the implementation of a modified protocol in April 1996, ten recipients ofliver (n=5), kidney (n=4), kidney + delayed islets (n= 1) have received multiple infusions of! x 10 8 cells/kg body weight/day for five consecutive days (day 0-4) post-Tx.
Immunosuppression (IS) was with tacrolimus and steroids; CellCept was added to this regimen in 32 study and 15 control patients. BM was isolated from the vertebral bodies (VB) of cadaveric donors by a method described previously 25 and infused intravenously without cryopreservation. The recipients were not conditioned nor was the BM modified prior to infusion. The unavailability of consent to retrieve VB from the cadaveric donors resulted in accrual of 115 recipients of liver (n=32), kidney (n= 19) , kidney + pancreas (n=20), kidney + delayed islets (n=2), heart (n=20), lung (n=!O), small bowel (n=7) and multiorgan (n= 1) who were followed as contemporaneous controls. Episodes of acute rejection were treated with dose adjustments of routine IS, whereas OKT3 was reserved for the treatment of steroid-resistant rejection.
In Vitro Monitoring
Using peripheral blood mononuclear cells (PBMC), the immune status of the recipients was monitored serially by mixed leukocyte reaction (MLR), limiting dilution assay and proliferation against recall antigens (ConA and PHA). Using primers specific for either HLA-allele or the sex-determining region of the Y (SRY) chromosome (in mal emfemale recipients), the presence of donor DNA was determined periodically in the study and control patients. Serial quantitative evaluations of donor cell chimerism in a selected cohort of study and control patients were performed using a modified limiting dilution PCR (LOA-PCR) assay. The multilineage character of chimerism was also ascertained by PCR detection of donor DNA in lineage+ cells sorted from recipients' PBMC. The evidence for the presence of donor DC progenitors and therefore of engraftment was obtained by propagation of recipients' PBMC in rhGM-CSF and rhIL-4-enriched cultures. Subsequent to enrichment for lineagenull/MHC class Ir popUlation, the presence of donor DNA within the sorted cells was confirmed by PCR analysis.
Clinical Outcome
The ancillary BM infusion was safe and no complications that could be uniquely attributed to this procedure were witnessed in any of the 199 study patients. All but lS/199 (9%) of BM-augmented recipients are alive compared to 13/115 (II %) of controls, who have died during the course of this follow-up (Table I) . Additionally, grafts in nine study and five control patients have been lost during their successive follow-up (Table I) . It is noteworthy that no deaths or graft losses in the augmented group were related to BM infusion. No evidence of any inimical complication was witnessed in any of the ten patients who have received multiple BM infusion during the course of their follow-up (5-154 days). All of the surviving patients have adequate graft function.
Whilst all patients remain IS-dependent, it is nonetheless interesting to note that steroid-free existence has been achieved in 61 % study and 40% control patients who are at least 12 months post-Tx (figure I). Equally significant however, is the observations that a:
I statistically higher number of kidney recipients in the study group (71 %) were weaned off steroids as compared to the controls.
I I

Incidence of Acute and Chronic
Rejection. The tempo, severity and cumula, tive incidence of acute cellular rejection was comparable (-60%) in patients in the stud~ and control groups. Graft versus host disease was witnessed in only two (l %) BM-augi mented recipients (both of liver) which for its resolution required minor dose adjustments of routine IS. Whilst histopathological changes pathognomonic of chronic rejection have 
Multilineage Chimerism and Evidence for Infused Donor Cell Engraftment. ~
The incidence of chimerism was much higher (94%) in the BM-augmented patients a~ compared to the controls (56%). Additionally, using LDA-PCR, the levels of chimerisri were found to be at least 10-100 fold higher in a selected cohort of study patients as com; pared to the controls. Furthermore, the presence of donor DNA in sorted lineage+ cell: provided unequivocal evidence of the multilineage nature of donor cell chimerism in BMaugmented patients. It must be emphasized that our ability to identify donor DNA in cui tured/sorted (lineage+/class It) cells generated from the PBMC of 4/5 evaluated stud} patients who were at least one year post-Tx provide sustenance to our claim that infusei marrow may have indeed engrafted.
In Vitro Immune Modulation.
A previously established criteria was used to ac cess the extent of donor-specific immune modulation in control and study patients. 26 At; two-year follow-up, a higher proportion ofBM-augmented liver (50%) and lung (60%) re (Figure 2) . On the contrary, there was a comparable degree ofimmunomodulation in study and control kidney and heart recipients at a similar duration of follow-up.
CONCLUSION
Whilst in rodents and large animals, donor-specific tolerance could be achieved in months or years, the expectation of a similar outcome in humans is perhaps erroneous. Given our experience with long-tenn successful organ transplant recipients who are currently being weaned off IS under a meticulously planned protocol, it is anticipated that only a select cohort of patients in this study will ever achieve a drug-free state perhaps years if not a decade after Tx.
